Lassa Fever Vaccine Shows Promise in First Human Trial
Researchers at the University of Maryland have successfully tested a dual-purpose vaccine for Lassa fever and rabies in a human clinical trial. The vaccine, named LASSARAB, showed safety and immune response in early testing, offering a potential solution for regions with limited healthcare access.
Why it matters
Lassa fever is a significant public health threat in West Africa with high mortality rates, and this dual vaccine could streamline immunization efforts in resource-poor settings.
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early clinical trial that tested a new dual vaccine against Lassa fever and rabies. The study, published today in the journal Nature Medicine, found that the vaccine was safe and induced immune responses against both viruses. There are currently no vaccines against Lassa fever on the market.
The article is a straightforward reporting of scientific findings from a clinical trial.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in